Latest Lipoprotein Lipase Deficiency Stories
A European Union agency for the evaluation of medicinal products is recommending the approval of a gene therapy treatment for a rare disease, which would be the first time a treatment of this kind has received the regulatory go-ahead for use in the West.
AMSTERDAM, May 10, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, provided today a status update on Glybera (alipogene tiparvovec), its gene therapy product under development for the treatment of lipoprotein lipase deficiency (LPLD). Following the submission of the Day 180 questions at the end of the first quarter to the European Medicines Agency (EMA) as part of Glybera's Market Authorisation Application...
In the news release, "Amsterdam Molecular Therapeutics Reports Full Year Results 2010" issued on 16 Feb 2011 06:00 GMT, by Amsterdam Molecular Therapeutics B.V AEX:AMT over PR Newswire, we are advised by a representative of the company that the full year figures should have been included in the dissemination.
AMSTERDAM, February 16, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2010. Key Highlights - Glybera(R) Marketing Authorisation Application remains on track with European Medicines Agency (EMA); - Responses to Day 120 questions submitted in November 2010; - Day 180 list of Outstanding Issues now received; - Raised EUR14.3 million...
- To writhe; struggle or twist about with more or less force; wriggle.
- To scribble, jot.